問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

List

1698Cases

2016-11-16 - 2020-01-31

Phase III

A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of SA237 as monotherapy in patients with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD).

  • Condition/Disease

    neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD)

  • Test Drug

    SA237

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

郭育呈
China Medical University Hospital

Division of Neurology

2014-02-01 - 2021-12-31

Phase III

A MULTICENTER, RANDOMIZED, ADDITION TO BASELINE TREATMENT, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SA237 IN PATIENTS WITH NEUROMYELITIS OPTICA (NMO) AND NMO SPECTRUM DISORDER (NMOSD)

  • Condition/Disease

    NEUROMYELITIS OPTICA (NMO) AND NMO SPECTRUM DISORDER (NMOSD)

  • Test Drug

    SA237

Participate Sites
5Sites

Terminated5Sites

郭育呈
China Medical University Hospital

Division of Neurology

2020-03-01 - 2021-12-31

Phase I

A Phase I Safety and Pharmacokinetic Study of CVM-1118 Extended-Release Capsules Administered Orally to Patients with Advanced Cancers

  • Condition/Disease

    Advanced Cancer

  • Test Drug

    CVM-1118 ER Capsule

Participate Sites
2Sites

Recruiting2Sites

2021-09-24 - 2022-12-28

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2012-07-01 - 2017-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-06-01 - 2014-08-31

Phase I/II

A Phase I/II, Open-label, Randomized, Active Control, Dose Finding Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of P1101 in Interferon-Naïve Subjects with Chronic Hepatitis B Virus Infection

  • Condition/Disease

    Hepatitis B virus

  • Test Drug

    P1101

Participate Sites
9Sites

Terminated9Sites

2012-05-01 - 2013-08-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Terminated15Sites

2010-12-01 - 2017-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-08-01 - 2020-07-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Terminated16Sites

2017-08-01 - 2020-04-30

Phase III

A multinational, multi-center, randomized, double-blind, active comparator, phase III clinical trial to evaluate the efficacy and safety of donepezil transdermal patch in patients with Alzheimer’s disease

  • Condition/Disease

    mild to moderate Alzheimer's disease patient

  • Test Drug

    Donepezil transdermal patch

Participate Sites
12Sites

Terminated12Sites

楊淵韓
Kaohsiung Municipal Ta-Tung Hospital

Division of Neurology

1 164 165 166 167 168 170
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB